Notably, simvastatin has been shown in several studies to improve cognitive performance, reduce the levels of Aβ peptides, and prevent neuronal loss in AD through its ability to reduce oxidative stress, inflammation, and apoptosis along with the promotion of IDE secretion and modulation of the PI3K/Akt and MAPK/ERK1/2 pathways [38–41]. This evidence concerns the gene MAPK3 and Alzheimer disease.